Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

BACKGROUND: Neoadjuvant chemotherapy with trastuzumab for patients with HER2-positive breast cancer can produce a pathological complete response in the breast in 30–65% of patients. We investigated the effect of the timing of trastuzumab administration with anthracycline and taxane neoadjuvant chemo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Buzdar, Aman U, Suman, Vera J, Meric-Bernstam, Funda, Leitch, A Marilyn, Ellis, Matthew J, Boughey, Judy C, Unzeitig, Gary, Royce, Melanie, McCall, Linda M, Ewer, Michael S, Hunt, Kelly K
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176878/
https://ncbi.nlm.nih.gov/pubmed/24239210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70502-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller